Effect of irbesartan on progression of chronic kidney disease
Phase 4
- Conditions
- Chronic kidney disease
- Registration Number
- JPRN-UMIN000006609
- Lead Sponsor
- Department of Nephrology, University of Tsukuba
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with hypertensive crisis 2) Pregant or possible pregnant patients 3)Bilateral renal artery stenosis 4)anemia (Hb<8g/dl) 5)liver dysfunction (ALT>200IU/L) 6)modelate renal dysfunction(eGFR<40ml/min) 7)hyperkalemia (serum potassium conc. >6mEq/L) 8)Allergic reaction to irbesartan
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Change of blood pressure 2. Change of urinary albumin and protein excretion
- Secondary Outcome Measures
Name Time Method Change of serum parameters related to metabolic syndrome (insulin, adiponectin, leptin, hsCRP, TNF alfa, IL-6)